Glucagon Market

Key Players: Novo Nordisk (DK), Sanofi (FR), Eli Lilly and Company (US), Boehringer Ingelheim (DE), Amgen(US), Pfizer (US), Bristol-Myers Squibb (US), Mylan (US)

Glucagon Market

Glucagon Market Research Report By Indication (Hypoglycemia, Diabetic Ketoacidosis, Other Indications), By Route of Administration (Intravenous, Subcutaneous, Intramuscular), By Glucagon Origin (Human, Synthetic, Animal-derived), By Dosage Form (Injectable, Nasal Spray, Other Dosage Forms) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035
ID: MRFR/HC/28295-HCR
128 Pages
Rahul Gotadki
Last Updated: May 15, 2026
Request Free Sample

Glucagon Market Summary

As per Market Research Future analysis, the Glucagon Market Size was estimated at 9.007 USD Billion in 2024. The Glucagon industry is projected to grow from 9.612 USD Billion in 2025 to 18.42 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 6.72% during the forecast period 2025 - 2035

Key Market Trends & Highlights

The Glucagon Market is experiencing robust growth driven by technological advancements and increasing diabetes prevalence.

  • The demand for glucagon products is rising significantly, particularly in North America, which remains the largest market.
  • Advancements in drug delivery systems are enhancing the efficacy and convenience of glucagon administration, especially in the subcutaneous segment.
  • Integration of digital health technologies is transforming patient management and education regarding hypoglycemia, the largest segment.
  • Key market drivers include the increasing prevalence of diabetes and rising awareness about hypoglycemia, particularly in the Asia-Pacific region, which is the fastest-growing market.

Market Size & Forecast

2024 Market Size 9.007 (USD Billion)
2035 Market Size 18.42 (USD Billion)
CAGR (2025 - 2035) 6.72%

Major Players

Novo Nordisk (DK), Sanofi (FR), Eli Lilly and Company (US), Boehringer Ingelheim (DE), Amgen(US), Pfizer (US), Bristol-Myers Squibb (US), Mylan (US)

Our Impact
Enabled $4.3B Revenue Impact for Fortune 500 and Leading Multinationals
Partnering with 2000+ Global Organizations Each Year
30K+ Citations by Top-Tier Firms in the Industry

Glucagon Market Trends

The Glucagon Market is currently experiencing notable transformations driven by various factors. The increasing prevalence of diabetes and hypoglycemia has led to a heightened demand for glucagon products, which are essential for managing severe hypoglycemic episodes. Furthermore, advancements in drug delivery systems, including developments in the glucagon delivery device market, glucagon delivery devices market, and related glucagon pen needles market, such as auto-injectors and pre-filled syringes, are enhancing patient compliance and convenience. This evolution in administration methods appears to be a pivotal aspect of the market's growth, as it addresses the challenges associated with traditional glucagon delivery. Additionally, the rising awareness of glucagon's role in emergency situations is fostering a more proactive approach to diabetes management, thereby expanding the market's reach and aligning with trends seen in the broader glucagon like peptide-1 market and glucagon like peptide 1 receptor agonist market.

Moreover, the Glucagon Market is likely to benefit from ongoing research and development efforts aimed at improving the efficacy and safety profiles of glucagon formulations. Collaborations between pharmaceutical companies and healthcare providers may lead to innovative solutions that cater to diverse patient needs. As the healthcare landscape evolves, parallels are also observed with adjacent therapeutic segments such as the glucagon like peptide 1 agonist market, antidiabetic glucagon like peptide 1 agonists market, glucagon like peptide 1 analogs market, glucagon-like peptide 1 analogues market, and glucagon-like peptide 1 glp-1 analogues market. The integration of digital health technologies, such as mobile applications for monitoring blood glucose levels, could further enhance the management of diabetes and hypoglycemia. Overall, the Glucagon Market appears poised for growth, driven by technological advancements, increased awareness, and a commitment to improving patient outcomes.

Rising Demand for Glucagon Market Products

The Glucagon Market is witnessing an upsurge in demand due to the increasing incidence of diabetes and related complications. As more individuals are diagnosed with diabetes, the need for effective management solutions becomes paramount. This trend indicates a shift towards proactive healthcare, supporting innovation across the glucagon injection market and connected segments like the glucagon like peptide 1 analogues market.

Advancements in Drug Delivery Systems

Innovations in drug delivery mechanisms are transforming the Glucagon Market. The introduction of user-friendly devices, such as auto-injectors, is likely to enhance patient adherence to treatment protocols. These advancements reflect growth trends in the glucagon delivery device market and regional developments such as the us glucagon delivery devices market.

Integration of Digital Health Technologies

The incorporation of digital health solutions into diabetes management is emerging as a significant trend within the Glucagon Market. Mobile applications and telehealth services are facilitating better monitoring and communication between patients and healthcare providers, complementing developments in related therapeutic areas like the glucagon like peptide 2 receptor pipeline drugs market.

Glucagon Market Drivers

Increasing Prevalence of Diabetes

The rising incidence of diabetes, particularly type 1 and type 2, is a primary driver for the Glucagon Market. As per recent statistics, the number of individuals diagnosed with diabetes continues to escalate, leading to a heightened demand for effective management solutions. Glucagon Market, as a critical hormone for counteracting severe hypoglycemia, plays a vital role in diabetes care. The market for glucagon products is projected to expand significantly, with estimates suggesting a compound annual growth rate (CAGR) of over 10% in the coming years. This trend indicates a robust growth trajectory for the Glucagon Market, as healthcare providers increasingly recognize the necessity of glucagon in diabetes management.

Regulatory Support for Glucagon Products

Regulatory bodies are playing a crucial role in shaping the Glucagon Market through supportive policies and guidelines. Recent approvals of new glucagon formulations and delivery methods have paved the way for increased market participation. Regulatory agencies are also encouraging research and development in this field, which may lead to the introduction of novel glucagon therapies. The favorable regulatory environment is likely to stimulate competition among manufacturers, resulting in a wider array of glucagon products available to consumers. This dynamic is expected to enhance the overall growth of the Glucagon Market, as companies strive to meet the evolving needs of patients and healthcare providers.

Growing Geriatric Population with Diabetes

The increasing geriatric population is a significant driver for the Glucagon Market. Older adults are more susceptible to diabetes and its complications, including hypoglycemia. As the global population ages, the demand for glucagon products is likely to rise correspondingly. This demographic shift necessitates tailored healthcare solutions, including glucagon, to manage diabetes effectively in older patients. Market analysts project that the geriatric segment will contribute substantially to the overall growth of the glucagon market, as healthcare systems adapt to the unique needs of this population. Consequently, the Glucagon Market is poised for expansion, driven by the imperative to provide effective diabetes management solutions for the aging population.

Rising Awareness and Education on Hypoglycemia

There is a growing emphasis on education regarding hypoglycemia and its management, which is positively influencing the Glucagon Market. Healthcare providers are increasingly focusing on training patients and caregivers about the importance of glucagon in emergency situations. This heightened awareness is likely to lead to increased prescriptions and usage of glucagon products. Educational initiatives, including workshops and online resources, are being implemented to inform patients about recognizing hypoglycemic symptoms and the appropriate use of glucagon. As awareness continues to rise, the Glucagon Market is expected to benefit from a surge in demand, as more individuals seek to be prepared for potential hypoglycemic events.

Technological Innovations in Glucagon Delivery

Advancements in drug delivery systems are transforming the Glucagon Market. Innovations such as prefilled syringes and auto-injectors are enhancing the ease of use and accessibility of glucagon products. These technologies not only improve patient compliance but also ensure timely administration during hypoglycemic episodes. The introduction of user-friendly devices is likely to attract a broader patient base, thereby expanding market reach. Furthermore, the integration of smart technology, such as mobile applications that remind users to carry their glucagon, is anticipated to bolster the market. As these innovations proliferate, the Glucagon Market is expected to witness substantial growth, driven by increased adoption rates among patients and healthcare professionals.

Market Segment Insights

By Indication: Hypoglycemia (Largest) vs. Diabetic Ketoacidosis (Fastest-Growing)

In the Glucagon Market, the Indication segment is prominently led by Hypoglycemia, which holds the largest market share due to its well-established use in emergency situations for insulin-overdose patients. This segment is evolutionary, reflecting an increasing awareness among healthcare professionals and the public about the importance of swift intervention in hypoglycemic episodes. Diabetic Ketoacidosis, while smaller in comparison, is the fastest-growing segment, thanks to an increasing prevalence of Type 1 Diabetes and the effectiveness of glucagon as a critical intervention in acute care settings. The growth trends in the Indication segment are predominantly driven by rising diabetes incidences globally, which necessitates the use of glucagon in varying situations. Moreover, the push for better emergency responses in diabetic crises coupled with advancing glucagon formulations is catalyzing the expansion of Diabetic Ketoacidosis as a key area for market growth. Additionally, growing patient awareness about glucagon's role in managing severe hypoglycemia and diabetic emergencies is further fueling market dynamics in this segment.

Hypoglycemia (Dominant) vs. Diabetic Ketoacidosis (Emerging)

Hypoglycemia is recognized as the dominant indication in the Glucagon Market, characterized by its critical and immediate need for treatment in emergencies. Patients experiencing low blood sugar levels require rapid intervention, and glucagon's role is indispensable in reversing such conditions. This necessity emphasizes the established frameworks for hypoglycemia management, embedding glucagon in care protocols, and driving steady demand. On the other hand, Diabetic Ketoacidosis, though emerging, is becoming increasingly relevant with the rise in diabetes cases. Timely administration of glucagon can be life-saving for patients in diabetic crises, promoting awareness among medical practitioners and driving market adoption. As glucagon formulations evolve, the market position of Diabetic Ketoacidosis is expected to strengthen, attracting further investments and research in this area.

By Route of Administration: Subcutaneous (Largest) vs. Intravenous (Fastest-Growing)

In the Glucagon Market, the distribution of market shares among the routes of administration reveals that subcutaneous injections currently dominate the landscape, attributed primarily to their ease of use and patient compliance. Intravenous administration, while less prevalent, is gaining traction due to its rapid onset of action, appealing especially in emergency situations. As the market evolves, these methods demonstrate varying levels of adoption influenced by both clinical efficacy and patient preferences.

Administration Methods: Subcutaneous (Dominant) vs. Intravenous (Emerging)

Subcutaneous administration of glucagon is recognized as the dominant route, mainly due to its simplicity and minimal invasiveness, making it a preferred option for home use by patients with diabetes. This method favors self-administration and increases patient compliance, thus bolstering its strong market position. On the other hand, intravenous administration is emerging swiftly, particularly in hospital settings, as it provides immediate therapeutic effects during acute hypoglycemic events. Although it requires trained healthcare professionals for administration, its appeal lies in the ability to achieve rapid increases in blood glucose levels in critical care scenarios.

By Glucagon Origin: Human (Largest) vs. Synthetic (Fastest-Growing)

In the Glucagon market, the Human-origin glucagon is currently the largest segment due to its widespread acceptance and established therapeutic use. It holds a significant market share as it is primarily used in emergency treatments and is recognized for its safety and efficacy. The Synthetic glucagon segment, while smaller in comparison, is rapidly gaining traction due to advancements in biotechnology and increasing interest from pharmaceutical companies. This segment caters to the growing demand for alternatives that offer specific advantages in dosing and administration.

Glucagon Origin: Human (Dominant) vs. Synthetic (Emerging)

Human glucagon is recognized for its historical presence in the market and is primarily sourced from human proteins, making it the dominant player in therapeutic applications. Its proven track record in emergency medical protocols, particularly for severe hypoglycemia, enhances its value in clinical settings. In contrast, Synthetic glucagon represents an emerging segment characterized by its laboratory production. This innovation allows for more consistent quality and the potential for novel delivery methods, which are particularly appealing in the evolving landscape of diabetes management. The increasing demand for convenience in administration drives interest in synthetic formulations.

By Dosage Form: Injectable (Largest) vs. Nasal Spray (Fastest-Growing)

In the Glucagon Market, the Injectable dosage form holds a significant share, being the most widely used and trusted by healthcare professionals. This segment benefits from established protocols and widespread familiarity, ensuring robust market penetration. Conversely, the Nasal Spray dosage form, while smaller in market share, is gaining attention due to its user-friendly administration and rapid onset of action, appealing to both patients and healthcare providers. The growth trends within the Dosage Form segment are driven by increasing incidences of diabetes and hypoglycemia, necessitating innovative solutions that cater to patient preferences. The Injectable form is solidifying its position due to reliable efficacy, while the Nasal Spray is emerging rapidly, supported by advancements in formulation technologies and a focus on improving patient adherence by reducing the anxiety associated with needles.

Injectable (Dominant) vs. Nasal Spray (Emerging)

The Injectable dosage form is the dominant player within the Glucagon Market, characterized by its established usage patterns and clinician support. This form has become synonymous with reliability and efficacy, cementing its preference among practitioners for treating severe hypoglycemic events. On the other hand, the Nasal Spray is emerging as a viable alternative, designed to be less intimidating for patients, particularly those who experience anxiety with injections. The ease of administration and rapid absorption profile of the Nasal Spray make it an attractive option, appealing to a wider patient population. As both forms coexist, the market is witnessing a dynamic evolution driven by patient-centric innovations and the pursuit of optimized therapeutic outcomes.

Get more detailed insights about Glucagon Market
Request Free Sample

Regional Insights

North America : Market Leader in Glucagon Market

North America is the largest market for glucagon, accounting for approximately 45% of the global share. The region’s leadership also aligns with strong growth in the North America glucagon-like peptide-1 agonists market, supported by advanced healthcare infrastructure and innovation. The region's growth is driven by increasing diabetes prevalence, advancements in glucagon formulations, and supportive regulatory frameworks. The U.S. leads this market, followed closely by Canada, which holds around 15% of the market share. Regulatory approvals for new glucagon products have further catalyzed market expansion, enhancing accessibility and affordability for patients. The competitive landscape in North America is robust, featuring key players such as Eli Lilly, Novo Nordisk, and Sanofi. These companies are actively engaged in innovation and strategic partnerships to enhance their product offerings. The presence of advanced healthcare infrastructure and a high level of awareness regarding diabetes management contribute to the region's strong market position. The focus on patient-centric solutions is expected to drive further growth in the coming years.

Europe : Emerging Market Dynamics

Europe is witnessing significant growth in the glucagon market, holding approximately 30% of the global share. The increasing incidence of diabetes and the rising demand for effective treatment options are key drivers. Germany and France are the largest markets in this region, accounting for about 10% and 8% of the market share, respectively. Regulatory initiatives aimed at improving diabetes care are also contributing to market expansion, fostering innovation and accessibility. Leading countries in Europe include Germany, France, and the UK, with major players like Sanofi and Boehringer Ingelheim dominating the landscape. The competitive environment is characterized by a mix of established companies and emerging startups focusing on novel glucagon formulations. The European Medicines Agency (EMA) continues to play a crucial role in regulating and approving new therapies, ensuring safety and efficacy for patients. This regulatory support is vital for sustaining market growth.

Asia-Pacific : Rapidly Growing Market

The Asia-Pacific region is rapidly emerging as a significant player in the glucagon market, currently holding about 20% of the global share. The growth is primarily driven by rising diabetes prevalence, increasing healthcare expenditure, and government initiatives aimed at improving diabetes management. China and India are the leading markets, contributing approximately 10% and 5% to the overall market share, respectively. The region's regulatory bodies are increasingly focusing on streamlining approval processes for new glucagon products, enhancing market access. In Asia-Pacific, the competitive landscape is evolving, with both multinational corporations and local players vying for market share. Key companies such as Eli Lilly and Amgen are actively investing in research and development to introduce innovative glucagon solutions. The growing awareness of diabetes management and the need for effective treatment options are expected to drive further growth in this region, making it a focal point for future investments.

Middle East and Africa : Emerging Opportunities Ahead

The Middle East and Africa (MEA) region is gradually emerging in the glucagon market, currently holding about 5% of the global share. The growth is driven by increasing diabetes prevalence and a rising focus on healthcare infrastructure development. Countries like South Africa and the UAE are leading the market, with a combined share of approximately 3%. Regulatory bodies in the region are beginning to implement policies aimed at improving access to diabetes treatments, which is expected to catalyze market growth in the coming years. The competitive landscape in MEA is characterized by a mix of local and international players. Companies such as Mylan and Pfizer are establishing a presence in the region, focusing on affordable glucagon solutions. The increasing awareness of diabetes management and the need for effective treatments are driving demand. As healthcare systems evolve, the MEA region presents significant opportunities for growth in the glucagon market, attracting investments and innovations.

Glucagon Market Regional Image

Key Players and Competitive Insights

Major competitors in the Glucagon Market industry are constantly working on strengthening their positions and increasing their market share. The leading Glucagon Market players are involved in active research and development to offer new innovative products and therapies that will meet the changing needs of patients. Partnerships, cooperation, and acquisitions are actively taking place in the liquid propane industry as companies are focused on strengthening their positions in crucial markets. The Glucagon Market growth is conditioned by various government and industry-led factors belonging to the market environment that work on its development and influence the market growth and development. Regarding the dynamics of competition, it is important to note that new players are constantly entering the market, and the existing companies are either acquiring new partners or expanding. Novo Nordisk is one of the leading companies in the global healthcare sector, occupying a strong position in the Glucagon Market industry. The company is highly praised for its extensive experience and innovations, which helped Novo Nordisk develop a powerful portfolio of first-class Glucagon Market products. The product is known for its quality, efficacy, safety, and high ease of use, which are critical factors influencing the company’s leading position on the market. Ongoing research and development and global outreach have significantly strengthened the company's position in Glucagon Market. Eli Lilly and Company is another important player in the Glucagon Market that has contributed to the product's development and commercialization. The company’s Glucagon Market products are of great quality and reliability and are highly suited for use. Eli Lilly and Company actively invests in research and development to expand the product portfolio and meet the emerging needs. Ease of administration and focus on patient care helps the company to hold a strong market position.

Key Companies in the Glucagon Market include

Industry Developments

The rising prevalence of diabetes, increasing demand for injectable glucagon, and growing adoption of continuous glucose monitoring (CGM) systems are primarily driving market growth.

Key industry developments include the launch of new products, such as Eli Lilly's Baqsimi nasal glucagon, and strategic collaborations between market players to expand their product portfolios. The market is also witnessing increasing investments in research and development of novel glucagon-based therapies, with a focus on non-injectable formulations and combination therapies.

Future Outlook

Glucagon Market Future Outlook

The Glucagon Market is projected to grow at a 6.72% CAGR from 2025 to 2035, driven by rising diabetes prevalence, technological advancements, and increased awareness of hypoglycemia management.

New opportunities lie in:

  • Development of glucagon auto-injectors for emergency use in schools and workplaces. Expansion of glucagon formulations for pediatric patients to enhance market reach. Partnerships with telehealth platforms for remote glucagon prescription and monitoring.

By 2035, the Glucagon Market is expected to achieve substantial growth, reflecting evolving healthcare needs.

Market Segmentation

Glucagon Market Indication Outlook

  • Hypoglycemia
  • Diabetic Ketoacidosis
  • Other Indications

Glucagon Market Dosage Form Outlook

  • Injectable
  • Nasal Spray
  • Other Dosage Forms

Glucagon Market Glucagon Origin Outlook

  • Human
  • Synthetic
  • Animal-derived

Glucagon Market Route of Administration Outlook

  • Intravenous
  • Subcutaneous
  • Intramuscular

Report Scope

MARKET SIZE 2024 9.007(USD Billion)
MARKET SIZE 2025 9.612(USD Billion)
MARKET SIZE 2035 18.42(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR) 6.72% (2025 - 2035)
REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR 2024
Market Forecast Period 2025 - 2035
Historical Data 2019 - 2024
Market Forecast Units USD Billion
Key Companies Profiled Novo Nordisk (DK), Sanofi (FR), Eli Lilly and Company (US), Boehringer Ingelheim (DE), Amgen (US), Pfizer (US), Bristol-Myers Squibb (US), Mylan (US)
Segments Covered Indication, Route of Administration, Glucagon Origin, Dosage Form, Regional
Key Market Opportunities Advancements in glucagon delivery systems enhance patient compliance and treatment efficacy in diabetes management.
Key Market Dynamics Rising demand for glucagon in diabetes management drives innovation and competitive dynamics among pharmaceutical companies.
Countries Covered North America, Europe, APAC, South America, MEA

FAQs

What is the projected market valuation of the Glucagon Market by 2035?

The Glucagon Market is projected to reach a valuation of 18.42 USD Billion by 2035.

What was the market valuation of the Glucagon Market in 2024?

In 2024, the Glucagon Market was valued at 9.007 USD Billion.

What is the expected CAGR for the Glucagon Market during the forecast period 2025 - 2035?

The expected CAGR for the Glucagon Market during the forecast period 2025 - 2035 is 6.72%.

Which companies are considered key players in the Glucagon Market?

Key players in the Glucagon Market include Novo Nordisk, Sanofi, Eli Lilly and Company, Boehringer Ingelheim, Amgen, Pfizer, Bristol-Myers Squibb, and Mylan.

What are the projected values for the Hypoglycemia segment by 2035?

The Hypoglycemia segment is projected to reach values between 7.5 USD Billion by 2035.

How does the Intravenous route of administration perform in the Glucagon Market?

The Intravenous route of administration is expected to grow to a value of 5.0 USD Billion by 2035.

What is the anticipated market performance for synthetic glucagon by 2035?

Synthetic glucagon is projected to achieve a market value of 6.0 USD Billion by 2035.

What dosage form is expected to dominate the Glucagon Market by 2035?

Injectable dosage forms are anticipated to dominate the market, reaching 11.5 USD Billion by 2035.

What is the projected market value for the Diabetic Ketoacidosis segment by 2035?

The Diabetic Ketoacidosis segment is projected to reach a value of 5.5 USD Billion by 2035.

What trends are influencing the growth of the Glucagon Market?

The growth of the Glucagon Market is influenced by increasing incidences of diabetes and advancements in glucagon formulations.

Author
Author
Author Profile
Rahul Gotadki LinkedIn
Research Manager
He holds an experience of about 9+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.
Get In Touch
Leave a Comment

Research Approach

Secondary Research

The secondary research process involved comprehensive analysis of regulatory databases, peer-reviewed medical journals, clinical publications, and authoritative health organizations. Key sources included the US Food & Drug Administration (FDA), European Medicines Agency (EMA), International Diabetes Federation (IDF), American Diabetes Association (ADA), European Association for the Study of Diabetes (EASD), National Institutes of Health (NIH), National Center for Biotechnology Information (NCBI/PubMed), Centers for Disease Control and Prevention (CDC) Diabetes Statistics, World Health Organization (WHO) Global Diabetes Compact, EU Eurostat Health Database, Centers for Medicare & Medicaid Services (CMS), Health Canada, Therapeutic Goods Administration (TGA) Australia, and national diabetes registry reports from key markets.

Diabetes prevalence data, clinical safety studies on managing hypoglycemia, emergency medicine protocols, demographic trends, and market landscape analysis for human, synthetic, and animal-derived glucagon formulations across injectable, nasal spray, and other dosage forms were gathered from these sources.

Primary Research

In order to gather both qualitative and quantitative insights, supply-side and demand-side stakeholders were interviewed during the primary research process. CEOs, VPs of Product Development, heads of regulatory affairs, and commercial directors from companies that make glucagon, biotechnology, and emergency medical devices were examples of supply-side sources. Board-certified endocrinologists, emergency medicine doctors, diabetes educators, hospital pharmacy directors, and procurement leaders from endocrinology clinics, emergency rooms, hospitals, and diabetes care facilities were among the demand-side sources. Primary research obtained information on clinical adoption patterns of intravenous, subcutaneous, and intramuscular administration routes, pricing strategies, and reimbursement dynamics for rescue glucagon therapies. It also validated market segmentation across hypoglycemia and diabetic ketoacidosis indications and confirmed product pipeline timelines for novel delivery mechanisms.

Primary Respondent Breakdown:

By Designation: C-level Primaries (32%), Director Level (30%), Others (38%)

By Region: North America (32%), Europe (30%), Asia-Pacific (28%), Rest of World (10%)

Market Size Estimation

Global market valuation was derived through revenue mapping and procedure volume analysis. The methodology included:

Identification of 40+ key manufacturers across North America, Europe, Asia-Pacific, and Latin America specializing in glucagon formulations

Product mapping across human origin, synthetic, and animal-derived glucagon categories

Analysis of reported and modeled annual revenues specific to glucagon portfolios including injectable kits, nasal sprays, and pre-filled pens

Coverage of manufacturers representing 72-77% of global market share in 2024

Extrapolation using bottom-up (diabetes prevalence × hypoglycemia incidence × treatment rates × ASP by country) and top-down (manufacturer revenue validation) approaches to derive segment-specific valuations for intravenous, subcutaneous, and intramuscular administration routes

Download Free Sample

Kindly complete the form below to receive a free sample of this Report

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.